MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urolonc.2026.111065

Медицинская библиотека · Urologic oncology · 2026

Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival.

Noel Onika D V, Akgul Burak, Bhandari Mukund, Ramos Francisco, Joshi Geeta, Garg Harshit, Dursun Furkan, Mansour Ahmed

СтатьяПеревод в очереди

Аннотация

BACKGROUND

To identify factors influencing clinical trial participation in genitourinary (GU) cancers, evaluate differences in survival, and address barriers to equitable enrollment.

METHODS

Using the National Cancer Database, we conducted a stage-matched cohort study of patients with kidney, bladder, and prostate cancers. Patients enrolled in clinical trials (CTs) were matched to nonparticipants by clinical stage. Logistic regression identified predictors of CT participation. Survival outcomes were assessed using inverse probability weighting-adjusted Kaplan-Meier curves and Cox models.

RESULTS

Among 668,400 kidney, 1.8 million prostate, and 721,733 bladder cancer patients, CT participation rates were 0.20%, 0.06%, and 0.04%, respectively. Black and Hispanic patients had lower participation in kidney and prostate cancer trials compared with non-Hispanic White patients (Black: OR 0.82, 95% CI, [0.68-0.98]; Hispanic: OR 0.86, 95% CI, [0.62-1.15]). Higher educational attainment (OR 2.28, 95% CI, [1.81-2.92], P < 0.001) and higher income (>63,000 USD: OR 1.57, 95% CI, [1.28-1.94], P < 0.001) were associated with increased participation. Among stage IV patients, trial participants demonstrated longer median survival in prostate cancer (61.5 vs. 28.8 months; 95% CI, 61.5-61.5 and 28.1-29.7) and kidney cancer (22.8 vs. 6.1 months; 95% CI, 20.5-22.8 and 5.9-6.3). In bladder cancer, median survival was similar between participants (14.1 months; 95% CI, 14.1-14.1) and nonparticipants (9.7 months; 95% CI, 9.5-10.0).

CONCLUSION

Participation in CTs is influenced by racial, ethnic, and socioeconomic factors and significantly improves survival in GU cancers; ensuring equitable enrollment is critical for the development of next-generation therapies.

Для цитирования: Noel Onika D V, Akgul Burak, Bhandari Mukund, Ramos Francisco, Joshi Geeta, Garg Harshit, Dursun Furkan, Mansour Ahmed. Clinical trial participation in kidney, bladder, and prostate malignancies in the United States: Sociodemographic distribution and impact on survival.. Urologic oncology. 2026. DOI: 10.1016/j.urolonc.2026.111065.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.